Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation

Takashi Tanaka, Yoshihiro Inamoto, Takuya Yamashita, Shigeo Fuji, Keiji Okinaka, Saiko Kurosawa, Sung Won Kim, Ryuji Tanosaki, Takahiro Fukuda

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Persistent thrombocytopenia is a common complication after allogeneic hematopoietic cell transplantation (HCT). Eltrombopag is an oral thrombopoietin receptor agonist whose efficacy against persistent thrombocytopenia after allogeneic HCT has not been well characterized. This retrospective study evaluated the safety and efficacy of eltrombopag in 12 consecutive patients with persistent thrombocytopenia after allogeneic HCT. Eltrombopag was started at 12.5 mg once daily and the dose was increased by 12.5 mg daily every week until platelet counts exceeded 50,000/μL. Five patients had prolonged isolated thrombocytopenia (PIT) and 7 patients had secondary failure of platelet recovery (SFPR). The cumulative incidence rate of successful platelet recovery to ≥50,000/μL without transfusion support was 60% in PIT patients and 71% in SFPR patients. No patients discontinued the drug because of adverse events or intolerability. Notably, the rate of platelet recovery was higher (100% versus 58%; P = .0017) and recovery was faster (median, 33 days versus 137 days; P = .0078) in patients with normal numbers of bone marrow megakaryocytes before starting eltrombopag than in those with decreased numbers of megakaryocytes. Eltrombopag is a promising treatment for both PIT and SFPR after allogeneic HCT. The number of megakaryocytes in bone marrow before eltrombopag treatment may predict the response to eltrombopag.

Original languageEnglish
Pages (from-to)919-924
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume22
Issue number5
DOIs
Publication statusPublished - 2016 May 1
Externally publishedYes

Fingerprint

Cell Transplantation
Thrombocytopenia
Blood Platelets
Megakaryocytes
Therapeutics
Thrombopoietin Receptors
Bone Marrow
eltrombopag
Drug-Related Side Effects and Adverse Reactions
Platelet Count
Retrospective Studies
Safety
Incidence

Keywords

  • Eltrombopag
  • Hematopoietic cell transplantation
  • Prolonged isolated thrombocytopenia
  • Secondary failure of platelet recovery
  • Thrombocytopenia

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation. / Tanaka, Takashi; Inamoto, Yoshihiro; Yamashita, Takuya; Fuji, Shigeo; Okinaka, Keiji; Kurosawa, Saiko; Kim, Sung Won; Tanosaki, Ryuji; Fukuda, Takahiro.

In: Biology of Blood and Marrow Transplantation, Vol. 22, No. 5, 01.05.2016, p. 919-924.

Research output: Contribution to journalArticle

Tanaka, T, Inamoto, Y, Yamashita, T, Fuji, S, Okinaka, K, Kurosawa, S, Kim, SW, Tanosaki, R & Fukuda, T 2016, 'Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation', Biology of Blood and Marrow Transplantation, vol. 22, no. 5, pp. 919-924. https://doi.org/10.1016/j.bbmt.2016.01.018
Tanaka, Takashi ; Inamoto, Yoshihiro ; Yamashita, Takuya ; Fuji, Shigeo ; Okinaka, Keiji ; Kurosawa, Saiko ; Kim, Sung Won ; Tanosaki, Ryuji ; Fukuda, Takahiro. / Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2016 ; Vol. 22, No. 5. pp. 919-924.
@article{e9d25be252024b3997c46bcec72b814a,
title = "Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation",
abstract = "Persistent thrombocytopenia is a common complication after allogeneic hematopoietic cell transplantation (HCT). Eltrombopag is an oral thrombopoietin receptor agonist whose efficacy against persistent thrombocytopenia after allogeneic HCT has not been well characterized. This retrospective study evaluated the safety and efficacy of eltrombopag in 12 consecutive patients with persistent thrombocytopenia after allogeneic HCT. Eltrombopag was started at 12.5 mg once daily and the dose was increased by 12.5 mg daily every week until platelet counts exceeded 50,000/μL. Five patients had prolonged isolated thrombocytopenia (PIT) and 7 patients had secondary failure of platelet recovery (SFPR). The cumulative incidence rate of successful platelet recovery to ≥50,000/μL without transfusion support was 60{\%} in PIT patients and 71{\%} in SFPR patients. No patients discontinued the drug because of adverse events or intolerability. Notably, the rate of platelet recovery was higher (100{\%} versus 58{\%}; P = .0017) and recovery was faster (median, 33 days versus 137 days; P = .0078) in patients with normal numbers of bone marrow megakaryocytes before starting eltrombopag than in those with decreased numbers of megakaryocytes. Eltrombopag is a promising treatment for both PIT and SFPR after allogeneic HCT. The number of megakaryocytes in bone marrow before eltrombopag treatment may predict the response to eltrombopag.",
keywords = "Eltrombopag, Hematopoietic cell transplantation, Prolonged isolated thrombocytopenia, Secondary failure of platelet recovery, Thrombocytopenia",
author = "Takashi Tanaka and Yoshihiro Inamoto and Takuya Yamashita and Shigeo Fuji and Keiji Okinaka and Saiko Kurosawa and Kim, {Sung Won} and Ryuji Tanosaki and Takahiro Fukuda",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.bbmt.2016.01.018",
language = "English",
volume = "22",
pages = "919--924",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation

AU - Tanaka, Takashi

AU - Inamoto, Yoshihiro

AU - Yamashita, Takuya

AU - Fuji, Shigeo

AU - Okinaka, Keiji

AU - Kurosawa, Saiko

AU - Kim, Sung Won

AU - Tanosaki, Ryuji

AU - Fukuda, Takahiro

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Persistent thrombocytopenia is a common complication after allogeneic hematopoietic cell transplantation (HCT). Eltrombopag is an oral thrombopoietin receptor agonist whose efficacy against persistent thrombocytopenia after allogeneic HCT has not been well characterized. This retrospective study evaluated the safety and efficacy of eltrombopag in 12 consecutive patients with persistent thrombocytopenia after allogeneic HCT. Eltrombopag was started at 12.5 mg once daily and the dose was increased by 12.5 mg daily every week until platelet counts exceeded 50,000/μL. Five patients had prolonged isolated thrombocytopenia (PIT) and 7 patients had secondary failure of platelet recovery (SFPR). The cumulative incidence rate of successful platelet recovery to ≥50,000/μL without transfusion support was 60% in PIT patients and 71% in SFPR patients. No patients discontinued the drug because of adverse events or intolerability. Notably, the rate of platelet recovery was higher (100% versus 58%; P = .0017) and recovery was faster (median, 33 days versus 137 days; P = .0078) in patients with normal numbers of bone marrow megakaryocytes before starting eltrombopag than in those with decreased numbers of megakaryocytes. Eltrombopag is a promising treatment for both PIT and SFPR after allogeneic HCT. The number of megakaryocytes in bone marrow before eltrombopag treatment may predict the response to eltrombopag.

AB - Persistent thrombocytopenia is a common complication after allogeneic hematopoietic cell transplantation (HCT). Eltrombopag is an oral thrombopoietin receptor agonist whose efficacy against persistent thrombocytopenia after allogeneic HCT has not been well characterized. This retrospective study evaluated the safety and efficacy of eltrombopag in 12 consecutive patients with persistent thrombocytopenia after allogeneic HCT. Eltrombopag was started at 12.5 mg once daily and the dose was increased by 12.5 mg daily every week until platelet counts exceeded 50,000/μL. Five patients had prolonged isolated thrombocytopenia (PIT) and 7 patients had secondary failure of platelet recovery (SFPR). The cumulative incidence rate of successful platelet recovery to ≥50,000/μL without transfusion support was 60% in PIT patients and 71% in SFPR patients. No patients discontinued the drug because of adverse events or intolerability. Notably, the rate of platelet recovery was higher (100% versus 58%; P = .0017) and recovery was faster (median, 33 days versus 137 days; P = .0078) in patients with normal numbers of bone marrow megakaryocytes before starting eltrombopag than in those with decreased numbers of megakaryocytes. Eltrombopag is a promising treatment for both PIT and SFPR after allogeneic HCT. The number of megakaryocytes in bone marrow before eltrombopag treatment may predict the response to eltrombopag.

KW - Eltrombopag

KW - Hematopoietic cell transplantation

KW - Prolonged isolated thrombocytopenia

KW - Secondary failure of platelet recovery

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=84963652910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963652910&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2016.01.018

DO - 10.1016/j.bbmt.2016.01.018

M3 - Article

C2 - 26785333

AN - SCOPUS:84963652910

VL - 22

SP - 919

EP - 924

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 5

ER -